363 related articles for article (PubMed ID: 28234925)
21. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.
Stojic J; Hagemann C; Haas S; Herbold C; Kühnel S; Gerngras S; Roggendorf W; Roosen K; Vince GH
Neurosci Res; 2008 Jan; 60(1):40-9. PubMed ID: 17980449
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.
Yamamoto M; Mohanam S; Sawaya R; Fuller GN; Seiki M; Sato H; Gokaslan ZL; Liotta LA; Nicolson GL; Rao JS
Cancer Res; 1996 Jan; 56(2):384-92. PubMed ID: 8542596
[TBL] [Abstract][Full Text] [Related]
23. Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors.
Tews DS; Nissen A
Invasion Metastasis; 1998-1999; 18(5-6):271-84. PubMed ID: 10729772
[TBL] [Abstract][Full Text] [Related]
24. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
25. Expression of cathepsin B and microvascular density increases with higher grade of astrocytomas.
Wang M; Tang J; Liu S; Yoshida D; Teramoto A
J Neurooncol; 2005 Jan; 71(1):3-7. PubMed ID: 15719267
[TBL] [Abstract][Full Text] [Related]
26. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.
Aaberg-Jessen C; Christensen K; Offenberg H; Bartels A; Dreehsen T; Hansen S; Schrøder HD; Brünner N; Kristensen BW
J Neurooncol; 2009 Oct; 95(1):117-128. PubMed ID: 19430729
[TBL] [Abstract][Full Text] [Related]
27. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas.
Nakamura M; Ishida E; Shimada K; Kishi M; Nakase H; Sakaki T; Konishi N
Lab Invest; 2005 Feb; 85(2):165-75. PubMed ID: 15592495
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin D is a potential serum marker for poor prognosis in glioma patients.
Fukuda ME; Iwadate Y; Machida T; Hiwasa T; Nimura Y; Nagai Y; Takiguchi M; Tanzawa H; Yamaura A; Seki N
Cancer Res; 2005 Jun; 65(12):5190-4. PubMed ID: 15958563
[TBL] [Abstract][Full Text] [Related]
29. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene.
Mayes DA; Hu Y; Teng Y; Siegel E; Wu X; Panda K; Tan F; Yung WK; Zhou YH
Cancer Res; 2006 Oct; 66(20):9809-17. PubMed ID: 17047041
[TBL] [Abstract][Full Text] [Related]
30. Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
Aaberg-Jessen C; Sørensen MD; Matos ALSA; Moreira JM; Brünner N; Knudsen A; Kristensen BW
BMC Cancer; 2018 Mar; 18(1):270. PubMed ID: 29523123
[TBL] [Abstract][Full Text] [Related]
31. N-cadherin, beta-catenin and connexin 43 expression in astrocytic tumours of various grades.
Reszec J; Szkudlarek M; Hermanowicz A; Bernaczyk PS; Mariak Z; Chyczewski L
Histol Histopathol; 2015 Mar; 30(3):361-71. PubMed ID: 25386667
[TBL] [Abstract][Full Text] [Related]
32. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
33. TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas.
Rorive S; Lopez XM; Maris C; Trepant AL; Sauvage S; Sadeghi N; Roland I; Decaestecker C; Salmon I
Mod Pathol; 2010 Oct; 23(10):1418-28. PubMed ID: 20693981
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence.
Zhou W; Yu X; Sun S; Zhang X; Yang W; Zhang J; Zhang X; Jiang Z
Biomed Pharmacother; 2019 Oct; 118():109369. PubMed ID: 31545229
[TBL] [Abstract][Full Text] [Related]
35. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
36. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
37. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines.
Mercapide J; Lopez De Cicco R; Castresana JS; Klein-Szanto AJ
Int J Cancer; 2003 Sep; 106(5):676-82. PubMed ID: 12866026
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Hara A; Okayasu I
Acta Neuropathol; 2004 Jul; 108(1):43-8. PubMed ID: 15088099
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells.
Lettau I; Hattermann K; Held-Feindt J; Brauer R; Sedlacek R; Mentlein R
J Neuropathol Exp Neurol; 2010 Mar; 69(3):215-23. PubMed ID: 20142769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
